Introduction
Year: 2022
Type: article
Abstract: Advances in the diagnosis and management of multiple myeloma (MM) and other plasma cell disorders such as AL amyloidosis and Waldenström macroglobulinemia (WM) continue to evolve rapidly. Over the past several years, there have been significant gains in understanding disease biology, leading to improvements in diagnostic techniques, a shift towards targeted therapies, and a potential transition away from traditional chemotherapeutic agents as the standard of care.
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4289712844